Key facts & figures
- To print this page, please use the File menu or press simultaneously ctrl + p keys.
- Send this page
Sanofi-aventis is a global healthcare company engaged in the research, development, manufacture and marketing of healthcare products. Our business is diversified and includes pharmaceuticals comprising Rx (prescription) drugs, OTC/OTX (over-the-counter / combined OTC and Rx drugs) and generics; vaccines and animal health.
- 2008 net sales: €27,568 million, +3,1%* versus 2007
- 2008 adjusted EPS excluding selected items*: €5.49, +6.2% versus 2007 or +11.2% at constant €/$ exchange rate
Pharmaceuticals business
Sanofi-aventis' pharmaceuticals business focuses on six therapeutic areas: thrombosis, cardiovascular diseases, diabetes, oncology, central nervous system (CNS) and internal medicine.
- 2008 net sales of the pharmaceuticals business: €24,707 million +3.1%* versus 2007
The Rx drugs(1) activity counts 5 leading brands with double-digit growth in 2008.
- 2008 net sales of Rx drugs: €22,943 million, +2.9%* versus 2007
- Market share: 4.8%
- Rank: #4
Pharmaceuticals business| €million | Therapeutic area | 2008 sales | % change*
(vs. 2007) |
|---|
| Lovenox® | Thrombosis | 2,738 | +10.6% |
|---|
| Plavix® | Thrombosis | 2,616 | +10.5% |
|---|
| Lantus® | Diabetes | 2,450 | +27.7% |
|---|
| Taxotere® | Oncology | 2,033 | +13.2% |
|---|
| Aprovel® | Cardiovascular | 1,202 | +14.2% |
|---|
Note: Worldwide presence* of Plavix® is €6,143 million, +15.3%. Worldwide presence* of Aprovel® is €1,966 million, +10.8%.
Sanofi-aventis also has a significant presence in OTC/OTX(2), in various product categories.
- 2008 net sales of OTC/OTX: €1,415 million, +5.3%* versus 2007
- Market share: 2.1%
- Rank: #6
In addition to Rx drugs and OTC/OTX, the pharmaceuticals business comprises generics(1).
- 2008 net sales of generics: €349 million, +8.7%* versus 2007
- Market share: <1%
- Rank: #23
With the acquisition of the generics company Zentiva, sanofi-aventis ranks 11th worldwide with a market share of 2.2%, based on pro forma 2008 sales of €999 million (IMS / Cegedim 2008 pro forma data).
(1) Market share and ranking from internal analysis based on IMS MIDAS MAT Q3 2008
(2) Market share and ranking from Nicholas Hall, 2007.
Vaccines business
Sanofi Pasteur, the fully integrated vaccines business(1) of sanofi-aventis, is the world leader in the vaccines industry offering the broadest range of vaccines in five areas: influenza, pediatric combinations and poliomyelitis vaccines, adult and adolescent booster vaccines, meningitis as well as travel, endemic and measles, mumps, rubella (MMR) vaccines.
- 2008 net sales of the vaccines business: €2,861 million, +9.6%* versus 2007
- Non-consolidated 2008 sales of Sanofi Pasteur MSD (50/50 joint-venture with Merck): €1,272 million, +21.8%
- Market share: 21.8%
- Rank: #1
2008 net sales of the vaccines business| € million | 2008 sales | % change*
(vs. 2007) |
|---|
| Polio/Whooping Cough/Hib Vaccines | 768 | +21.9% |
|---|
| Influenza vaccines | 736 | +1.5% |
|---|
| Meningitis/pneumonia vaccines | 472 | +7.0% |
|---|
| Adult booster vaccine | 399 | +8.1% |
|---|
| Travel vaccines | 309 | -1.6% |
|---|
| Other vaccines | 177 | +34.1% |
|---|
| TOTAL | 2,861 | +9.6% |
|---|
(1) Market share and rank based on sanofi pasteur internal estimates at end Dec. 2008 and on worldwide presence including 50% of Sanofi Pasteur MSD joint-venture sales.
Animal health
Merial, a 50-50 joint venture with Merck, is one of the world’s leading animal health(1) companies dedicated to the research, development, manufacture and delivery of innovative pharmaceuticals and vaccines used by veterinarians, farmers and pet owners.
- Non-consolidated 2008 sales of Merial: $2,643 million, +7.9% versus 2007
- Market share: 14%
- Rank: #3
(1) Market share and ranking based on 2007 public data
Geographic presence
Sanofi-aventis has a commercial presence in approximately 100 countries, and our products are available in more than 170 countries. Our presence is well-balanced between traditional (Europe, North America and Japan) and emerging markets. Sanofi-aventis is the established leader in emerging markets, holding top positions in the main countries.
2008 Geographic presence| € million | 2008 sales | % change*
(vs. 2007) |
|---|
| Europe | 12,096 | -0.6% |
|---|
| United States | 8,609 | +5.4% |
|---|
| Other countries | 6,863 | +10.1% |
|---|
* See our Glossary for the definition of financial indicators
Changes in our sales are stated on a “comparable” basis.
